Physician profile
David Kaminskas
NPI 1023202843
$119,775.64
in general payments reported to CMS, 2019-2025
41 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $858 · 2021: $6,232 · 2022: $28K · 2023: $32K · 2024: $27K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $8,906 · Travel and Lodging: $5,739 · Consulting Fee: $1,215 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,175.00 |
| Food and Beverage | $8,906.08 |
| Travel and Lodging | $5,738.82 |
| Consulting Fee | $1,215.00 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $110,977.83 | 2021-2025 | |
| Pfizer INC. | $1,526.63 | 2024-2025 | |
| Allergan, INC. | $1,160.50 | 2019-2022 | |
| Lundbeck LLC | $881.57 | 2020-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $838.84 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Merz Pharmaceuticals, LLC | $494.26 | 2021-2023 | Xeomin |
| Genentech USA, INC. | $324.48 | 2025 | Ocrevus Zunovo, Ocrevus, Tnkase |
| Alexion Pharmaceuticals, INC. | $322.81 | 2024-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $320.08 | 2024 | Ingrezza |
| Lilly USA, LLC | $259.17 | 2019-2024 | Kisunla |
| Amgen INC. | $248.15 | 2019-2024 | Uplizna |
| Vanda Pharmaceuticals INC. | $235.94 | 2025 | Ponvory |
| Biohaven Pharmaceuticals, INC. | $232.96 | 2021 | |
| Jazz Pharmaceuticals INC. | $201.95 | 2019-2023 | |
| Livanova USA, INC. | $200.70 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaminskas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.